ERBB2 and breast cancer: Considering that breast cancer patients have elevated HER2 blood concentrations (15–75 ng/mL) in comparison with those observed for normal individuals (2–15 ng/mL) [62], this methodology allows discrimination between a healthy patient and a patient with HER2 overexpression and, therefore, at risk of breast cancer.